Junne Kamihara, MD, PhD of Dana-Farber Cancer Institute explains the significance of the shift from single gene testing to multiplex testing.This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.
Advertisement
Advertisement